Shanghai Longcheer Technology's H-share issue price is not more than HK$31 per share.

08:13 14/01/2026

Longqi Technology (603341.SH) announced that the company published the prospectus for the issuance and listing of H shares on the Hong Kong Stock Exchange website on January 14, 2026. The base number of H shares to be issued globally in this offering is 52.2591 million shares (subject to exercise of the over-allotment option), and in the event that the over-allotment option is fully exercised, the maximum number of H shares to be issued globally in this offering is 60.0979 million shares. The price for this H share offering will not exceed HK$31 per share. The public offering of H shares in Hong Kong began on January 14, 2026, is expected to end on January 19, 2026, and the issue price is expected to be announced by January 20, 2026.

Shanghai Longcheer Technology (603341.SH) announced that on January 14, 2026, the company published the prospectus for the H-share offering on the Hong Kong Stock Exchange website. The company's global H-share offering will consist of a basic offering of 52.2591 million shares (subject to the exercise of over-allotment option), with a maximum offering size of 60.0979 million shares if the over-allotment option is fully exercised. The maximum offering price for the H-share offering will not exceed HK$31 per share. The public offering of H-shares in Hong Kong began on January 14, 2026, is expected to end on January 19, 2026, and the offering price is scheduled to be announced on or before January 20, 2026.

HK Stock Market Move | XTALPI (02228) rises by over 4% again, ReviR's innovative drug RTX-117 obtains clinical approval in China and the United States.

HK Stock Market Move | Zunshan (03317) continues to rise by over 6% to a new high, plans to enter into a strategic partnership with GOLDSTREAM INV to promote the development of real-time data infrastructure, and so on.

HK Stock Market Move | WEIMOB INC (02013) increases by over 8% again, GEO final market volume is large, Weimob, as a head player with early layout, may be the first to benefit.

HK Stock Market Move | XTALPI (02228) rises by over 4% again, ReviR's innovative drug RTX-117 obtains clinical approval in China and the United States.

HK Stock Market Move | WEIMOB INC (02013) increases by over 8% again, GEO final market volume is large, Weimob, as a head player with early layout, may be the first to benefit.